Fady Ibraham Malik, who serves as Executive Vice President of Research & Development at Cytokinetics INC (NASDAQ:CYTK), reported the sale of 12,033 shares of the company's common stock on March 17, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The transactions were completed at an execution price of $62.15 per share. The filing breaks the sale into two tranches: 7,636 shares in the first transaction, which produced proceeds of $474,577, and 4,397 shares in the second, which generated $273,273. After these transactions, the filing shows Malik directly holds 153,902 shares of Cytokinetics INC.
Footnotes included with the Form 4 indicate the sales were "sell-to-cover" transactions. The company compelled those sales to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units (RSUs).
Separately, InvestingPro analysis included with the filing notes that the stock appears undervalued at current levels. The note points readers to comprehensive Pro Research Reports covering CYTK and more than 1,400 additional U.S. equities for deeper research.
These insider transactions arrive as several major financial firms have updated their outlooks and price targets for Cytokinetics. The following analyst moves were cited in the filing or related disclosures:
- Mizuho raised its price target for Cytokinetics to $100, citing an extension of aficamten’s intellectual property to 2041 and greater confidence in the company’s non-obstructive hypertrophic cardiomyopathy program.
- JPMorgan increased its price target to $75, pointing to a favorable near-term outlook after the approval of Myqorzo for obstructive hypertrophic cardiomyopathy.
- Stifel reiterated its Buy rating and kept a $98 price target, expressing optimism about forthcoming data from the company’s ACACIA trial.
- Leerink Partners reaffirmed an Outperform rating with an $84 price target, noting management’s confidence in the U.S. launch of Myqorzo and the anticipated ACACIA-HCM Phase 3 readout in 2026.
- UBS raised its price target to $69 on increased confidence in the non-obstructive hypertrophic cardiomyopathy program, while maintaining a Neutral rating.
Collectively, these analyst updates reflect varied but generally positive sentiment about Cytokinetics’ prospects, particularly around its cardiac drug programs and upcoming clinical readouts. The insider sell-to-cover trades described in the Form 4 are presented as routine tax-withholding actions tied to RSU vesting rather than discretionary selling to raise capital.
Investors seeking additional valuation context were directed to InvestingPro tools and research reports noted in the filings.
Note: The details above are drawn from the Form 4 filing and the analyst commentary cited in the company disclosures. Where the disclosures are limited, those limitations are reflected rather than expanded upon.